Should biochemical markers of bone turnover be considered standard practice for safety pharmacology

Biomarkers

Volumn 15, Issue 3, 2010, Pages 195-204

  Henriksen, K ^a   Bohren, K M ^b   Bay Jensen, A C ^a   Karsdal, M A ^a,c,d  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Immunodiagnostic Systems Inc   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d CCBR/SYNARC   (Denmark)

Author keywords

Bone markers; Critical Path Initiative; Safety pharmacology

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; BALAGLITAZONE; BETA 2 MICROGLOBULIN; BIOCHEMICAL MARKER; CATHEPSIN K; CHOLESTEROL; CLUSTERIN; COLLAGEN TYPE 1; CREATININE; CYSTATIN C; CYTOCHROME P450; DRUG METABOLIZING ENZYME; GLIBENCLAMIDE; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; THIOPURINE METHYLTRANSFERASE; TREFOIL PEPTIDE; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR MARKER;

ADIPOGENESIS; APOPTOSIS; BLOOD SAMPLING; BONE DENSITY; BONE MATRIX; BONE METABOLISM; BONE TURNOVER; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; FRACTURE; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; LIVER TOXICITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHARMACODYNAMICS; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

BIOCHEMISTRY; BIOLOGICAL MARKERS; BONE AND BONES; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; PHARMACOLOGY; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77951687483     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903434519     Document Type: Review

References (104)

1. Adams CP, Brantner VV. (2006). Estimating the cost of new drug development: is it really 802 million dollars? Health Af (Millwood) 25:420-428
2. Ali AA, Weinstein RS, Stewart SA et al. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast diferentiation and bone formation. Endocrinology 146:1226-1235
3. Arnaud CH. (2006). Systems Biology's Clinical Future. Chem Eng News 84:17-26.
4. Bauer DC, Hunter DJ, Abramson SB et al. (2006). Classifcation of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:723-727
5. Berberoglu Z, Gursoy A, Bayraktar N et al. (2007). Rosiglitazone decreases serum bone-specifc alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523-3530
6. Bergmann P, Body JJ, Boonen S et al. (2009). Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63:19-26.
7. Bingham CO III, Pohl C, Woodworth TG et al. (2009). Developing a standardized defnition for disease 'fare' in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 36:2335-2341
8. Binkley N, Krueger D, Gemar D et al. (2008). Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804-1808
9. Biomarkers Defnitions Working Group. (2008). Biomarkers and surrogate endpoints: Preferred defnitions and conceptual framework. Clin Pharmacol Ter 69:89-95.
10. Black DM, Delmas PD, Eastell R et al. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
11. Black DM, Schwartz AV, Ensrud KE et al. (2006). Efects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
12. Bonde M, Qvist P, Fledelius C et al. (1995). Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864-868
13. Brasso K, Christensen IJ, Johansen JS et al. (2006). Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66:503-513
14. Broyles DL, Nielsen RG, Bussett EM et al. (1998). Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 44:2139-2147
15. Caplan L, Saag KG. (2009). Glucocorticoids and the risk of osteoporosis. Expert Opin Drug Saf 8:33-47.
16. Carter GD, Carter CR, Gunter E et al. (2004a). Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 89-90:467-471
17. Carter GD, Carter CR, Jones J et al. (2004b). How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50:2195-2197
18. Chesnut CH III, Silverman S, Andriano K et al. (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267-276
19. Christgau S, Bitsch-Jensen O, Hanover BN et al. (2000). Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505-511
20. Christgau S, Rosenquist C, Alexandersen P et al. (1998). Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290-2300
21. Christgau S, Tanko LB, Cloos PA et al. (2004). Suppression of elevated cartilage turnover in postmenopausal women and in ovariect-omized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11:508-518
22. Coleman R, Brown J, Terpos E et al. (2008). Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629-639
23. Conaghan PG, Bird P, McQueen F et al. (2009). Te OMERACT MRI infammatory arthritis group: advances and future research priorities. J Rheumatol 36:1803-1805
24. Cornish J, Callon KE, Bava U et al. (2002). Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175:405-415
25. Covey SD, Wideman RD, McDonald C et al. (2006). Te pancreatic beta cell is a key site for mediating the efects of leptin on glucose homeostasis. Cell Metab 4:291-302.
26. Cremers S, Garnero P. (2006). Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66:2031-2058
27. Delmas PD, Eastell R, Garnero P et al. (2000). Te use of biochemical markers of bone turnover in osteoporosis. Committee of Scientifc Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 (Suppl. 6):S2-17.
28. DiMasi JA, Hansen RW, Grabowski HG. (2003). Te price of innovation: new estimates of drug development costs. J Health Econ 22:151-185
29. Ducy P, Amling M, Takeda S et al. (2000). Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207.
30. Engvall IL, Svensson B, Tengstrand B et al. (2008). Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ter 10:R128.
31. Finley Austin MJ, Babiss L. (2006). Commentary: where and how could biomarkers be used in 2016? AAPS J 8:E185-9.
32. Gale EA. (2001). Lessons from the glitazones: a story of drug development. Lancet 357:1870-1875
33. Gale EA. (2006). Troglitazone: the lesson that nobody learned? Diabetologia 49:1-6.
34. Garnero P, Bianchi F, Carlier MC et al. (2000a). [Biochemical markers of bone remodeling: pre-analytical variations and guidelines for their use. SFBC (Societe Francaise de Biologie Clinique) Work Group. Biochemical markers of bone remodeling]. Ann Biol Clin (Paris) 58:683-704.
35. Garnero P, Ferreras M, Karsdal MA et al. (2003). Te type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-867
36. Garnero P, Hausherr E, Chapuy MC et al. (1996). Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538
37. Garnero P, Sornay-Rendu E, Claustrat B et al. (2000b). Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15:1526-1536
38. Gelb BD, Shi GP, Chapman HA et al. (1996). Pycnodysostosis, a lysosomal disease caused by cathepsin K defciency. Science 273:1236-1238
39. Gertz BJ, Clemens JD, Holland SD et al. (1998). Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102-106
40. Goldfne AB. (2008). Te rough road for rosiglitazone. Curr Opin Endocrinol Diabetes Obes 15:113-117
41. Goodsaid F, Frueh F. (2007). Biomarker qualifcation pilot process at the US Food and Drug Administration. AAPS J 9:E105-8.
42. Grey A. (2008). Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129-137
43. Grey A, Bolland M, Gamble G et al. (2007). Te peroxisome prolifer-ator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmeno-pausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310
44. Hansdottir H, Franzson L, Prestwood K et al. (2004). Te efect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779-783
45. Henriksen K, Byrjalsen I, Nielsen RH et al. (2009). A comparison of glycemic control, water retention, and musculoskeletal efects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol 616:340-345
46. Hinoi E, Gao N, Jung DY et al. (2008). Te sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 183:1235-1242
47. Hoegh-Andersen P, Tanko LB, Andersen TL et al. (2004). Ovariectomized rats as a model of postmenopausal osteoarthri-tis: validation and application. Arthritis Res Ter 6:R169-80.
48. Hwang JS, Tu ST, Yang TS et al. (2006). Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17:373-378
49. Kahn SE, Hafner SM, Heise MA et al. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
50. Kahn SE, Zinman B, Lachin JM et al. (2008). Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845-851
51. Karsdal MA, Henriksen K, Leeming DJ et al. (2009). Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14:181-202.
52. Karsdal MA, Martin TJ, Bollerslev J et al. (2007). Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487-494
53. Karsenty G. (2006). Convergence between bone and energy homeos-tases: leptin regulation of bone mass. Cell Metab 4:341-348
54. Kim HJ, Zhao H, Kitaura H et al. (2006). Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152-2160
55. Kim SW, Park DJ, Park KS et al. (2005). Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667-674
56. Kung AW, Pasion EG, Sofyan M et al. (2006). A comparison of teri-paratide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 22:929-937
57. Lee NK, Sowa H, Hinoi E et al. (2007). Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469
58. Leeming DJ, Alexandersen P, Karsdal MA et al. (2006). An update on biomarkers of bone turnover and their utility in bio-medical research and clinical practice. Eur J Clin Pharmacol 62:781-792
59. Leeming DJ, Byrjalsen I, Qvist P et al. (2008). Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation? BMC Cancer 8:180.
60. Lehmann JM, Moore LB, Smith-Oliver TA et al. (1995). An antidi-abetic thiazolidinedione is a high afnity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956
61. Lesko LJ, Atkinson AJ Jr. (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347-366
62. Liu S, Zhou J, Tang W et al. (2006). Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38-49.
63. Martin A, Vittoris R, David V et al. (2005). Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 146:3652-3659
64. McClung MR, Lewiecki EM, Cohen SB et al. (2006). Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
65. Meier C, Seibel MJ, Kraenzlin ME. (2009). Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24:386-388
66. Minisola S, Del FR, Piemonte S et al. (2008). Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 31:28-32.
67. Morioka T, Asilmaz E, Hu J et al. (2007). Disruption of leptin receptor expression in the pancreas directly afects beta cell growth and function in mice. J Clin Invest 117:2860-2868
68. Moyer-Mileur LJ, Slater H, Jordan KC et al. (2008). IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 23:1884-1891
69. Nishi Y, Atley L, Eyre DE et al. (1999). Determination of bone markers in pycnodysostosis: efects of cathepsin K defciency on bone matrix degradation. J Bone Miner Res 14:1902-1908
70. O'Neill RT. (2006). FDA's critical path initiative: a perspective on contributions of biostatistics. Biom J 48:559-564
71. Okabe R, Inaba M, Nakatsuka K et al. (2004). Signifcance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deox-ypyridinoline. J Bone Miner Metab 22:127-131
72. Okazaki R, Miura M, Toriumi M et al. (1999). Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795-801.
73. OMERACT. (1993). Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. 1993. Proceedings. Maastricht, Te Netherlands, April 29-May 3, 1992. J Rheumatol 20:527-591
74. Overgaard K, Riis BJ, Christiansen C et al. 1989. Efect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 299:477-479
75. Quarles LD. (2008). Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820-3828
76. Ravn P, Hosking D, Tompson D et al. (1999). Monitoring of alen-dronate treatment and prediction of efect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
77. Ravn P, Tompson DE, Ross PD et al. (2003). Biochemical markers for prediction of 4-year response in bone mass during bisphospho-nate treatment for prevention of postmenopausal osteoporosis. Bone 33:150-158
78. Ravn P, Weiss SR, Rodriguez-Portales JA et al. (2000). Alendronate in early postmenopausal women: efects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85:1492-1497
79. Reginster JY, Henrotin Y, Christiansen C et al. (2001). Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specifc for telopeptide derived degradation products of collagen type I. Calcif. Tissue Int. 69:130-217
80. Robins SP, Woitge H, Hesley R et al. (1994). Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specifc marker for measuring bone resorption. J Bone Miner Res 9:1643-1649
81. Roodman GD. (1999). Cell biology of the osteoclast. Exp Hematol 27:1229-1241
82. Rosen CJ. (2007). Te rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844-846
83. Rosen J, Miner JN. (2005). Te search for safer glucocorticoid receptor ligands. Endocr Rev 26:452-464
84. Rosenquist C, Fledelius C, Christgau S et al. (1998). Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin Chem 44:2281-2289
85. Rosenquist C, Qvist P, Bjarnason N et al. (1995). Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445
86. Rousseau JC, Delmas PD. (2007). Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3:346-356
87. Roux C, Garnero P, Tomas T et al. (2005). Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 72:26-31. (Pubitemid 40169960)
88. Rzonca SO, Suva LJ, Gaddy D et al. (2004). Bone is a target for the anti-diabetic compound rosiglitazone. Endocrinology 145:401-406
89. Sassi ML, Eriksen H, Risteli L et al. (2000). Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367-373
90. Schaller S, Henriksen K, Hoegh-Andersen P et al. (2005). In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553-580
91. Schaller S, Henriksen K, Sveigaard C et al. (2004). Te chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ova-riectomized rats without changing bone formation. J Bone Miner Res 19:1144-1153
92. Schwartz AV. (2008). TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008:297893.
93. Seeman E, Delmas PD. (2006). Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
94. Seibel MJ. (2005). Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97-122.
95. Seibel MJ. (2006). Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27:123-138
96. Shi Y, Yadav VK, Suda N et al. (2008). Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci USA 105:20529-20533
97. Soroceanu MA, Miao D, Bai XY et al. (2004). Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216
98. Sottile V, Seuwen K, Kneissel M. (2004). Enhanced marrow adipogen-esis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337
99. Spiegelman BM, Flier JS. (1996). Adipogenesis and obesity: rounding out the big picture. Cell 87:377-389
100. Tanko LB, Bagger YZ, Alexandersen P et al. (2004). Safety and efcacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month efects on biomarkers of bone turnover. J Bone Miner Res 19:1531-1538
101. Tontonoz P, Spiegelman BM. (2008). Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289-312.
102. van Brussel MS, Bultink IE, Lems W F. (2009). Prevention of gluco-corticoid-induced osteoporosis. Expert Opin Pharmacother 10:997-1005.
103. Vihinen MK, Kolho KL, Ashorn M et al. (2008). Bone turnover and metabolism in paediatric patients with infammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 159:693-698
104. Woodcock J, Woosley R. (2008). Te FDA critical path initiative and its infuence on new drug development. Annu Rev Med 59:1-12.